Unlock instant, AI-driven research and patent intelligence for your innovation.

Antibody specifically binding to SARS-COV-2 antigen protein, and use of antibody

A technology for COVID-19, sars-cov-2, applied in antiviral immunoglobulin, antibody, immunoglobulin, etc.

Active Publication Date: 2020-11-24
江苏集萃医学免疫技术研究所有限公司
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is currently no vaccine available to prevent COVID-19

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody specifically binding to SARS-COV-2 antigen protein, and use of antibody
  • Antibody specifically binding to SARS-COV-2 antigen protein, and use of antibody
  • Antibody specifically binding to SARS-COV-2 antigen protein, and use of antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0064] The following examples, applications, illustrations and descriptions are exemplary and explanatory and should not be construed as limiting the scope of the invention.

[0065] TCR and BCR repertoires show dynamic changes with COVID-19 disease progression

[0066] In this study, we investigated PBMC samples from patients at different stages of COVID-19 disease. Through immune repertoire analysis, we identified patterns of TCR and BCR dynamics during disease processes. Results The repertoire of TCR and BCR showed dynamic changes during the course of COVID-19. We collected 23 samples from COVID-19 patients at different disease stages ( Figure 5 ). The cohort consisted of 4 men and 6 women with a median age of 57 years (range, 33-81 years). Peripheral blood mononuclear cells (PBMC) were collected for at least one time point. 4 samples were collected from 3 patients ranging from early stage to recovery stage ( Figure 5 ). Peripheral blood samples were normally colle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an antibody specifically binding to a SARS-COV-2 antigen protein, and a use of the antibody. The invention provides an isolated or non-naturally occurring SARS-CoV-2 monoclonal antibody, and the monoclonal antibody comprises: (a) heavy chains CDR1, CDR2 and CDR3 represented by a Kabat number and having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with heavy chains CDR1, CDR2 and CDR3 shown in SEQ ID NOS: 78, and (b) light chains CDR1, CDR2 and CDR3 represented by a Kabat number and having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with light chains CDR1, CDR2 and CDR3 shown in SEQ ID NOS: 80. The antibody of the invention can be used as a therapeutic agent for treating COVID-19 or as adiagnostic tool for evaluating the COVID-19 infection in subjects.

Description

technical field [0001] The present invention relates to virus antibody and its application, especially relates to SARS-CoV-2 monoclonal antibody and its medical application. Background technique [0002] In 2019, the coronavirus disease (coronavirus disease-19, COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) was reported. This virus is highly related to the 2003 SARS-CoV. The virus primarily affects the lungs, but can also affect multiple organs including the kidneys, liver, brain, and gastrointestinal tract. The virus is spread through respiratory droplets, urine and feces. Clinical symptoms of SARS-CoV-2 included fever, cough, and shortness of breath in the absence of other pathogens, and pneumonia characterized by bilateral glassy opacity on chest CT imaging. Most COVID-19 patients present with mild or moderate syndrome and can recover after appropriate clinical care, while some COVID-19 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N5/10G01N33/577G01N33/569A61K39/42A61P31/14
CPCC07K16/10C12N5/0635G01N33/577G01N33/56983A61P31/14C07K2317/565C07K2317/56C07K2317/76C07K2317/92C12N2510/04G01N2333/165G01N2469/10
Inventor 俞逢佳牛学峰李松陈凌
Owner 江苏集萃医学免疫技术研究所有限公司